lung in Medical Technology

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. Th...

Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis

MORGANTOWN, W.Va., June 5 /PRNewswire-USNewswire/ -- It's common knowledge that smoking raises risks of lung cancer. And yet researchers haven't known whether continued smoking by lung cancer patients would increase the risk of the cancer's spread. Researchers at West Virginia Univers...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...

American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission

WASHINGTON, May 4 /PRNewswire-USNewswire/ -- As the confirmed number of H1N1 Flu (Swine Flu) cases grows in the United States, public concern understandably grows. The American Lung Association wishes to ease public concern by offering proven advice on how to prevent the spread of contagious respi...

Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG

ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Cal...

American Lung Association Study to be Published in the 'New England Journal of Medicine' Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought

--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux-- WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezi...

Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it has reached its enrollment target of 400 patients in the SPEAR (Study of Picoplatin Efficacy After Relapse) tria...

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

CALGARY, March 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced today that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients w...

CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth

SUNNYVALE, Calif., March 2 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today significant growth in CyberKnife lung cancer treatments in calendar year 2008. The number of lung cancer patients treated with CyberKnife radi...

Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis

CPF Calls on Manufacturer and FDA to Expedite Review of Pirfenidone as Treatment for PF SAN JOSE, Calif., Feb. 4 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is calling this a historic time in the research and treatment of PF, as a pivotal Phase III clinical trial is ...

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination...

American Lung Association Celebrates 101st Annual Christmas Seals Campaign

Visit www.christmasseals.org to learn more, make a donation or send a Christmas Seals e-card WASHINGTON, Nov. 17 /PRNewswire-USNewswire/ -- Millions will receive Christmas Seals in the mail this month, courtesy of the American Lung Association. These decorative holiday stamps are part o...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

Data also found SYMBICORT opened airways in less than 15 minutes WILMINGTON, Del., Oct. 29 /PRNewswire-FirstCall/ -- Data presented today from two pivotal efficacy and safety trials, SHINE and SUN, demonstrated that SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol...

Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years

Results published in New England Journal of Medicine reaffirm well-established efficacy and long-term safety profile of SPIRIVA(R) HandiHaler(R) RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNewswire/ -- Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropiu...

BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test

REHOVOT, Israel, September 24 /PRNewswire-FirstCall/ -- BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported today results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer. In the trial a total of 76 sputum samples we...

Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence

Study Shows near 80% Improvement In Outcomes PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally inv...

Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections

ZURICH, Switzerland, September 4 /PRNewswire/ -- Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an establis...

American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast

WASHINGTON, Sept. 1 /PRNewswire-USNewswire/ -- There has been recent concern that suicide may be a complication of montelukast (Singulair) therapy. Montelukast is a Food and Drug Administration (FDA) approved oral drug that has been prescribed for more than a decade for the treatment of asthma...

Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and ...

BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial

- Second instance where survival increase is observed in advanced non-small cell lung cancer patients receiving Tavocept in conjunction with standard chemotherapy - Median survival increase of 6.5 months seen for patients with adenocarcinoma, the most comm...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

-- Peregrine's Second Phase II Bavituximab Cancer Trial Is Evaluating the Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and Paclitaxel -- TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ...

Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report

SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and trea...

Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections

Data Presented at the European Cystic Fibrosis Society Conference MONMOUTH JUNCTION, N.J., June 13 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace(TM) (liposomal amikacin for inhalation). The compound i...

Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer

Collaboration Will Seek to Identify Unique microRNA Signatures That Will Predict Risk of Recurrence in Lung Cancer Patients The Project Will Leverage Rosetta Genomics' Proprietary microRNA Extraction and Quantification Technologies, and M. D. Anderson's Extensive Know-How ...

IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients

- Data presented at 44th American Society of Clinical Oncology (ASCO) annual meeting further supports improvement in median survival vs. external controls - IRVINE, Calif., June 2 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ) today announced follow-...

Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women

CHICAGO, June 1 /PRNewswire/ -- Physicians at the Karmanos Cancer Institute today presented the conclusions of their study, Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Result (SEER) Registry at the American Soc...

New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma

Gene Expression Profiling of Tumor is Correlated With Clinical Response CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by GlaxoSmithKline (GSK) today highlighted the potential of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) through results of three...

Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer

- Final study report expected in June 2008 - MORRISTOWN, N.J., April 30 /PRNewswire/ -- Vicus Therapeutics, LLC, a biopharmaceutical company focused on oncology supportive care, announced today the completion of the last patient visit in its study VT1-CAX-001, a Phase 2 trial of ...

Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit

- Final Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung Cancer Conference - SOUTH SAN FRANCISCO, Calif., April 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announce...

Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women

SAN DIEGO, April 14 /PRNewswire-USNewswire/ -- Researchers at the Barbara Ann Karmanos Cancer Institute in Detroit today presented findings that support the role of inflammation in determining lung cancer risk, particularly among African-American women. (Logo: http://www.newscom.com/cgi-b...

Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment

Poster Presented at the 2008 AACR Annual Meeting SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising r...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

HAYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study ...

Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients

Data from 150 lung transplant patients demonstrates potential to improve management of risk for infection BOSTON, April 10 /PRNewswire/ -- A prospective analysis of data collected from 170 patients receiving lung transplantation at the University of Pittsburgh Medical Center...

Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients

BOSTON, April 10 /PRNewswire/ -- Data presented at this week's 28th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) suggest the potential of a significant impact of using biomarkers to reduce the need for biopsies and personalize t...

Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting

Company seeks to collaborate on latest research technologies ALBUQUERQUE, N.M., April 10 /PRNewswire-FirstCall/ -- Researchers and executives from Biomoda, Inc. (OTC Bulletin Board: BMOD) ( http://www.biomoda.com ), a development stage medical diagnostics company, will present a paper en...

Independent Studies Report on Possible Roles for Cylex's Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients

Six different studies will report on use of ImmuKnow assay in presentations at the annual meeting of the International Society for Heart and Lung Transplantation COLUMBIA, Md., April 9 /PRNewswire/ -- Since it was initially cleared as an in vitro diagnostic techniqu...

New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting

BOSTON, April 9, 2008 /PRNewswire/ -- New devices and research for mechanical circulatory support in pediatrics from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) Pediatric Circulatory Support Program will be discussed at the International Society fo...

Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that data from a Phase 2 trial of picoplatin, the Company's lead product candidate, in patients with small cell ...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. A...